Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions.
暂无分享，去创建一个
[1] A. Lavrijsen,et al. Hepatic injury associated with itraconazole , 1992, The Lancet.
[2] L. Juhlin. Loss of taste and terbinafine , 1992, The Lancet.
[3] V. Sakhuja,et al. Fluconazole-induced thrombocytopenia. , 1990, Annals of internal medicine.
[4] D. Stevens,et al. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. , 1987, Reviews of infectious diseases.
[5] K. Ishak,et al. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. , 1984, Gastroenterology.
[6] H. Haverkamp,et al. Anaphylactic reactions to ketoconazole. , 1983, British medical journal.
[7] D. Worthington,et al. Is serum gamma-glutamyltransferase a misleading test? , 1983, British medical journal.
[8] D. Stevens,et al. Ketoconazole blocks testosterone synthesis. , 1982, Archives of internal medicine.
[9] D. Stevens,et al. Ketoconazole blocks adrenal steroid synthesis. , 1982, Annals of internal medicine.
[10] R. Chiprut,et al. Intrahepatic cholestasis after griseofulvin administration. , 1976, Gastroenterology.
[11] H. Breinstrup,et al. [Intrahepatic cholestasis after griseofulvin therapy]. , 1966, Ugeskrift for laeger.
[12] A. Redeker,et al. Effect of Griseofulvin in Acute Intermittent Porphyria. , 1964 .
[13] Calnan Cd. Drug reactions with griseofulvin. , 1960 .